Biotech Values

[drbio45]

he must be a real jackass


I think 230 million for a company like this, with a drug like this, that may work for diabetic neuropothy, is a cheap valuation.

This drug working like this should add some credibilty to their pipeline.

Everyone complains about Yakatan but one thing that I have seen is so far his drugs seem to work. I can't say that about most ceo's with supposedly more credibility.

I will take the drugs working and hope for the best.